Lung-Resident Memory Th2 Cells in Asthma

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Study completion date changed from estimate of Dec 15, 2027 to Sep 8, 2026
    • Interventions: Airway Brushing (Procedure), Bronchoscopy/BAL (Procedure) to Airway Brushing (Procedure), Bronchoscopy/BAL (Procedure)
    • Eligibility criteria shortened, about 1 word
  2. Study completion date: Dec 15, 2025 to Dec 15, 2027v8
  3. Primary completion date changed from estimate of Dec 2023 to Nov 15, 2024v7 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 120 to confirmed 37
    • Study completion date: Dec 2024 to Dec 15, 2025
    • Site details revised
  4. Primary completion date: Dec 2022 to Dec 2023
    • Study completion date: Dec 2023 to Dec 2024
    • Site contact updated
    v6
  5. Interventions: Airway Brushing (Procedure), Bronchoscopy/BAL (Procedure), Endobronchial Biopsy (Procedure) to Airway Brushing (Procedure), Bronchoscopy/BAL (Procedure)v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date changed from estimate of Oct 1, 2018 to May 23, 2019v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 2018 to Oct 1, 2018
    • Study sites: 0 to 1
    v3
  3. Eligibility criteria shortened, about 126 words
    • Study description expanded, about 5 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype. \~5-10% of effector Th2 cells recruited into the lung give rise to long-lived tissue resident memory cells that are poised to respond upon allergen re-exposure.Consequently, targeting memory Th2 cell activation is an attractive therapeutic strategy. However, it is not well understood how allergen inhalation initiates a memory Th2 cell response in the lung. The focus of this new study on the role of lung-resident memory Th2 cells in orchestrating the recall response to allergen in the lung, including the recruitment and activation of circulating Th2 cells, is a natural, timely and exciting extension of the investigators' ongoing Allergen Challenge Protocol.
Trial Details
NCT Number NCT03455959
Lead Sponsor Andrew D. Luster, M.D.,Ph.D.
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
(from sponsor)		 Asthma, Allergic
Related terms Asthma, Inflammation
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov